Nyxoah (NASDAQ:NYXH) Given New $15.00 Price Target at HC Wainwright

Nyxoah (NASDAQ:NYXH) had its price objective cut by equities research analysts at HC Wainwright from $17.00 to $15.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 61.88% from the company’s previous close.

Separately, Stifel Nicolaus reduced their price objective on Nyxoah from $16.00 to $15.00 and set a “buy” rating for the company in a report on Friday, March 14th.

Nyxoah Stock Performance

NYXH stock traded down $2.06 during trading on Wednesday, hitting $9.27. The company had a trading volume of 265,835 shares, compared to its average volume of 45,135. The firm has a 50-day moving average price of $10.50 and a 200-day moving average price of $9.35. The company has a quick ratio of 4.95, a current ratio of 5.28 and a debt-to-equity ratio of 0.21. The firm has a market cap of $315.60 million, a PE ratio of -4.97 and a beta of 1.42. Nyxoah has a 1-year low of $6.76 and a 1-year high of $14.20.

Nyxoah (NASDAQ:NYXH) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.03). Nyxoah had a negative return on equity of 51.68% and a negative net margin of 1,043.93%. The company had revenue of $1.35 million for the quarter, compared to analyst estimates of $2.02 million. On average, analysts expect that Nyxoah will post -1.91 earnings per share for the current year.

Institutional Investors Weigh In On Nyxoah

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vestal Point Capital LP acquired a new position in Nyxoah in the 4th quarter valued at about $23,394,000. Renaissance Technologies LLC acquired a new stake in Nyxoah during the fourth quarter worth approximately $187,000. Kovack Advisors Inc. grew its stake in Nyxoah by 100.0% in the 4th quarter. Kovack Advisors Inc. now owns 20,000 shares of the company’s stock worth $160,000 after acquiring an additional 10,000 shares during the period. Geode Capital Management LLC lifted its stake in shares of Nyxoah by 19.4% during the 4th quarter. Geode Capital Management LLC now owns 17,100 shares of the company’s stock worth $137,000 after purchasing an additional 2,774 shares during the period. Finally, Ameriprise Financial Inc. purchased a new position in Nyxoah during the fourth quarter worth about $135,000.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.